COGNETIVITY NEUROSCIENCES LTD. Cognetivity Neurosciences Ltd. Share Price
Equities
CGN
CA19243C1005
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.02 CAD | 0.00% |
|
0.00% | +33.33% |
| Sales 2022 | - | Sales 2023 | 0.05 0.06 3.78 | Capitalization | 21.26M 29.06M 1.77B |
|---|---|---|---|---|---|
| Net income 2022 | -13M -17.77M -1.08B | Net income 2023 | -7M -9.57M -584M | EV / Sales 2022 | - |
| Net cash position 2022 | 82.43K 113K 6.87M | Net cash position 2023 | 953K 1.3M 79.49M | EV / Sales 2023 | 44,76,67,262 x |
| P/E ratio 2022 |
-2.95
x | P/E ratio 2023 |
-2.86
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.56% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 month | +33.33% | ||
| 3 months | +33.33% | ||
| 6 months | -85.19% | ||
| Current year | +33.33% |
1 week
0.02
0.02
1 month
0.020.05
Current year
0.010.05
1 year
0.010.35
3 years
0.011.35
5 years
0.001.35
10 years
0.001.35
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 35 | 08/19/08 | |
Sina Habibi
FOU | Founder | 43 | 01/13/01 |
Thomas Sawyer
DFI | Director of Finance/CFO | 54 | 08/19/08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | - | |
Karimah Es Sabar
BRD | Director/Board Member | 66 | 20/23/20 |
Sina Habibi
FOU | Founder | 43 | 01/13/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/24/25 | 0.02 | 0.00% | 30,000 |
| 24/24/24 | 0.02 | 0.00% | 55,054 |
| 23/24/23 | 0.02 | +33.33% | 20,000 |
| 22/24/22 | 0.015 | -25.00% | 5,250 |
| 19/24/19 | 0.02 | 0.00% | 3,388 |
Delayed Quote Canadian Securities Exchange, April 25, 2024 at 11:22 pm IST
More quotes
Cognetivity Neurosciences Ltd. is a Canada-based technology company. The Company has developed a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial and consumer environments for potentially allowing early diagnosis of dementia. The Companyâs ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of brain. Its products include CognICA and OptiMind. The CognICA has various applications from providing a measure of cognitive function, to long-term health monitoring, corporate wellness, and personalized brain health. The OptiMind is a wellness app that measures individuals everyday cognitive performance. The Company serves various industries, including healthcare, elder care, enterprise, everyday use, and research. The ICA is available for clinical use in the United States of America, United Kingdom and Europe.
Calendar
05/06/2024
- Q4 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +33.33% | 1.37M | |
| +4.36% | 32.47B | |
| +14.14% | 7.45B | |
| +22.93% | 3.89B | |
| -16.29% | 3.15B | |
| -25.96% | 1.28B | |
| -36.14% | 1.09B | |
| -35.42% | 902M | |
| -0.13% | 893M | |
| -24.12% | 857M |
- Stock Market
- Equities
- CGN Stock
